Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 8/20 | 0.44 |
| ▸ | CHRNA6 | Q15825 | 8/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23231374 | 1.00 | NR1H2 (0.48) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL1979623 | 0.87 | NR1H2 (0.56) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL994561 | 0.87 | NR1H2 (0.56) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL25409415 | 0.87 | NR1H2 (0.56) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL23906938 | 0.82 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2KDM4EDDB1 | |
| SCHEMBL15313304 | 0.81 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2KDM4EDDB1 | |
| SCHEMBL24884312 | 0.78 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL22169156 | 0.78 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL400513 | 0.78 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL608991 | 0.78 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | NR1H2 4365/4885CHRNB2 4870/4885CHRNA3 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.